Covidien to acquire CNS Therapeutics

Mallinckrodt Inc., the pharma business of Covidien plc (NYSE:COV), will acquire specialty pharma CNS Therapeutics Inc. (St. Paul, Minn.) for about $100 million in cash. CNS markets Gablofen baclofen t...